ClinicalTrials.gg
CompletedNCT06733688Updated Dec 13, 2024

A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)

A Phase 1 interventional study of Tedizolid Phosphate Oral Formulation 1 (Reference) and Tedizolid Phosphate Oral Formulation 2 (Test) in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 19 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Apr 2022, 4 years 7 months ago, and no results have been posted to the registry.
  • Registered 2 years 8 months after the study started (first participant enrolled Mar 2022, registered Dec 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
19 Years to 60 Years
Sex
All
01

Study summary

The goal of the study is to learn what happens to different oral formulations of tedizolid phosphate (MK-1986) in a healthy person's body over time. Researchers want to know if there is a difference in the absorption and elimination of different oral formulations from the healthy person's body.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • Is in good health before randomization
  • Has a (BMI) ≥18.5 and ≤34 kg/m\^2, inclusive

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • Has a history of endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Has a history of clinically significant cancer ()
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Tedizolid Phosphate Oral Formulation 1 (Reference)

    Participants receive tedizolid phosphate formulation 1 orally.

    Drug: Tedizolid Phosphate Oral Formulation 1 (Reference)

  • Experimental
    Tedizolid Phosphate Oral Formulation 2 (Test)

    Participants receive tedizolid phosphate formulation 2 orally.

    Drug: Tedizolid Phosphate Oral Formulation 2 (Test)

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Tedizolid

    Blood samples will be collected to determine the AUC0-Inf of tedizolid.

    Time frame: At designated time points (up to 3 days postdose)

  2. Area Under the Concentration-Time Curve from Time 0 to the Last Measurable Concentration (AUC0-t) of Tedizolid

    Blood samples will be collected to determine the AUC0-t of tedizolid.

    Time frame: At designated time points (up to 3 days postdose)

  3. Maximum Plasma Concentration (Cmax) of Tedizolid

    Blood samples will be collected to determine the Cmax of tedizolid.

    Time frame: At designated time points (up to 3 days postdose)

Secondary outcomes

  1. Time to Maximum Plasma Concentration (Tmax) of Tedizolid

    Blood samples will be collected to determine the Tmax of tedizolid.

    Time frame: At designated time points (up to 3 days postdose)

  2. Apparent Terminal Half-Life (t1/2) of Tedizolid

    Blood samples will be collected to determine the t1/2 of tedizolid.

    Time frame: At designated time points (up to 3 days postdose)

  3. Apparent Volume of Distribution of Tedizolid After Nonintravenous Administration (Vd/F)

    Blood samples will be collected to determine the Vd/F of tedizolid.

    Time frame: At designated time points (up to 3 days postdose)

  4. Oral Clearance (CL/F) of Tedizolid

    Blood samples will be collected to determine the CL/F of tedizolid.

    Time frame: At designated time points (up to 3 days postdose)

  5. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Up to approximately 2 weeks

  6. Number of Participants Who Discontinue Study Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Up to approximately 2 weeks

07

Study locations

1 site
  • Celerion (Site 0001)
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Apr 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2024
First posted
Dec 13, 2024
StartActual
Mar 23, 2022
Primary completionActual
Apr 15, 2022
CompletionActual
Apr 15, 2022
Last update
Dec 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06733688
Responsible party
Sponsor
First posted
Dec 13, 2024
Start date
Mar 23, 2022
Primary completion
Apr 15, 2022
Completion
Apr 15, 2022
Last update
Dec 13, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tedizolid phosphate

Start the discussion